To date, three different targeted therapies against BRAF and MEK have been approved for the treatment of advanced unresectable/metastatic melanoma, namely, vemurafenib plus cobimetinib, dabrafenib plus trametinib, and encorafenib plus binimetinib [2,3,4]. The gene discussed is BRAF; the disease is metastatic melanoma.